Log in | Register

Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis

Tomoko Fujii| Riki Ganeko| Yuki Kataoka| Toshi A. Furukawa| Robin Featherstone| Kent Doi| Jean-Louis Vincent| Daniela Pasero| René Robert| Claudio Ronco| Sean M. Bagshaw
Systematic Review
Volume 44, Issue 2 / February , 2018

Pages 167 - 178

Abstract

Purpose

Polymyxin B-immobilized hemoperfusion (PMX-HP) is an adjuvant therapy for sepsis or septic shock that clears circulating endotoxin. Prior trials have shown that PMX-HP improves surrogate endpoints. We aimed to conduct an evidence synthesis to evaluate the efficacy and safety of PMX-HP in critically ill adult patients with sepsis or septic shock.

Methods

We searched for randomized controlled trials (RCTs) in MEDLINE, EMBASE, the Cochrane Library, the Health Technology Assessment Database, CINAHL, “Igaku Chuo Zasshi”, the National Institute of Health Clinical Trials Register, the World Health Organization International Clinical Trials Registry Platform, the University Hospital Medical Information Network Clinical Trials Registry, the reference lists of retrieved articles, and publications by manufacturers of PMX-HP. The primary outcomes were 28-day all-cause mortality, the number of patients with at least one serious adverse event, and organ dysfunction scores. The GRADE methodology for the certainty of evidence was used.

Results

Six trials (857 participants; weighted mean age 62.5 years) proved eligible. Patient-oriented primary outcomes were assessed. The pooled risk ratio (RR) for 28-day mortality associated with PMX-HP was 1.03 [95% confidence interval (CI) 0.78–1.36; I2 = 25%; n = 797]. The pooled RR for adverse events was 2.17 (95% CI 0.68–6.94; I2 = 0%; n = 717). Organ dysfunction scores over 24–72 h after PMX-HP treatment did not change significantly (standardized mean difference − 0.26; 95% CI − 0.64 to 0.12; I2 = 78%; n = 797). The certainty of the body of evidence was judged as low for both benefit and harm using the GRADE methodology.

Conclusions

There is currently insufficient evidence to support the routine use of PMX-HP to treat patients with sepsis or septic shock.

Registration

PROSPERO International Prospective Register of Systematic Reviews (CRD42016038356).

Keywords

References

  1. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R (2014) Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA 311:1308–1316
    • View reference on publisher's website
    • View reference on PubMed
  2. Rhee C, Dantes R, Epstein L et al (2017) CDC prevention epicenter program: benchmarking the incidence and mortality of severe sepsis in the United States. JAMA. https://doi.org/10.1001/jama.2017.13836(Epub ahead of print)
  3. Quenot JP, Binquet C, Kara F et al (2013) The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study. Crit Care 17:R65
    • View reference on publisher's website
    • View reference on PubMed
  4. Leligdowicz A, Dodek PM, Norena M, Co-operative Antimicrobial Therapy of Septic Shock Database Research Group et al (2014) Association between source of infection and hospital mortality in patients who have septic shock. Am J Respir Crit Care Med 189:1204–1213
    • View reference on publisher's website
    • View reference on PubMed
  5. Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801–810
    • View reference on publisher's website
    • View reference on PubMed
  6. Suffredini AF, Munford RS (2011) Novel therapies for septic shock over the past 4 decades. JAMA 306:194–199
    • View reference on publisher's website
    • View reference on PubMed
  7. Dellinger RP, Carlet JM, Masur H, Surviving Sepsis Campaign Management Guidelines Committee et al (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858–873
    • View reference on publisher's website
    • View reference on PubMed
  8. Dellinger RP, Levy MM, Rhodes A, Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41:580–637
    • View reference on publisher's website
    • View reference on PubMed
  9. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE (1991) Endotoxemia in human septic shock. Chest 99:169–175
    • View reference on publisher's website
    • View reference on PubMed
  10. Casey LC, Balk RA, Bone RC (1993) Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119:771–778
    • View reference on publisher's website
    • View reference on PubMed
  11. Marshall JC, Foster D, Vincent JL, MEDIC study et al (2004) Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 190:527–534
    • View reference on publisher's website
    • View reference on PubMed
  12. Shoji H, Tani T, Hanasawa K, Kodama M (1998) Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: designing and antiendotoxin efficacy in the clinical application. Ther Apher 2:3–12
    • View reference on publisher's website
    • View reference on PubMed
  13. Shoji H (2003) Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 7:108–114
    • View reference on publisher's website
    • View reference on PubMed
  14. Vincent JL, Laterre PF, Cohen J et al (2005) A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23:400–405
    • View reference on publisher's website
    • View reference on PubMed
  15. Cruz DN, Antonelli M, Fumagalli R et al (2009) Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301:2445–2452
    • View reference on publisher's website
    • View reference on PubMed
  16. Cruz DN, Perazella MA, Bellomo R et al (2007) Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 11:R47
    • View reference on publisher's website
    • View reference on PubMed
  17. Payen DM, Guilhot J, Launey Y, ABDOMIX Group et al (2015) Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 41:975–984
  18. Dellinger P (2016) EUPHRATES: evaluating the use of polymyxin B hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock. Canadian Critical Care Forum, Toronto
  19. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097
    • View reference on publisher's website
    • View reference on PubMed
  20. Fujii T, Ganeko R, Kataoka Y, Featherstone R, Bagshaw S, Furukawa TA (2016) Polymyxin B-immobilised haemoperfusion and mortality in critically ill patients with sepsis/septic shock: a protocol for a systematic review and meta-analysis. BMJ Open 6:e012908
    • View reference on publisher's website
    • View reference on PubMed
  21. Levy MM, Fink MP, Marshall JC, International Sepsis Definitions Conference et al (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med 29:530–538
  22. Vincent JL, de Mendonça A, Cantraine F et al (1998) Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med 26:1793–1800
    • View reference on publisher's website
    • View reference on PubMed
  23. Sampson M, McGowana J, Cogob E, Grimshaw J, Moherd D, Lefebvre C (2009) An evidence-based practice guideline for the peer review of electronic search strategies. J Clin Epidemiol 62:944–952
    • View reference on publisher's website
    • View reference on PubMed
  24. Higgins JPT, Green S (2008) Cochrane handbook for Systematic Reviews of Interventions. John Wiley & Sons, Chichester (UK)
  25. Vincent JL, Moreno R, Takala J et al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710
  26. Cook R, Cook D, Tilley J, Lee K, Marshall J, Canadian Critical Care Trials Group (2001) Multiple organ dysfunction: baseline and serial component scores. Crit Care Med 29:2046–2050
    • View reference on publisher's website
    • View reference on PubMed
  27. da Costa BR, Nüesch E, Rutjes AW et al (2013) Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study. J Clin Epidemiol 66:847–855
    • View reference on publisher's website
    • View reference on PubMed
  28. Review Manager (RevMan) [Computer program] (2014) Version 5.3. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen
  29. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
    • View reference on publisher's website
    • View reference on PubMed
  30. Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383–394
    • View reference on publisher's website
    • View reference on PubMed
  31. Cantaluppi V, Assenzio B, Pasero D et al (2008) Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med 34:1638–1645
  32. Nakamura T, Ushiyama C, Suzuki Y et al (2003) Combination therapy with polymyxin B-immobilized fibre haemoperfusion and teicoplanin for sepsis due to methicillin-resistant Staphylococcus aureus. J Hosp Infect 53:58–63
    • View reference on publisher's website
    • View reference on PubMed
  33. Berto P, Ronco C, Cruz D, Melotti RM, Antonelli M (2011) Cost-effectiveness analysis of polymyxin-B immobilized fiber column and conventional medical therapy in the management of abdominal septic shock in Italy. Blood Purif 32:331–340
    • View reference on publisher's website
    • View reference on PubMed
  34. Klein DJ, Foster D, Schorr CA, Kazempour K, Walker PM, Dellinger RP (2014) The EUPHRATES trial (evaluating the use of polymyxin B hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock): study protocol for a randomized controlled trial. Trials. 15:218
    • View reference on publisher's website
    • View reference on PubMed
  35. Honore PM, Jamez J, Wauthier M et al (2000) Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 28:3581–3587
    • View reference on publisher's website
    • View reference on PubMed
  36. Bellomo R, Kellum JA, Gandhi CR et al (2000) The effect of intensive plasma water exchange by hemofiltration on hemodynamics and soluble mediators in canine endotoxemia. Am J Respir Crit Care Med 161:1429–1436
    • View reference on publisher's website
    • View reference on PubMed
  37. Cornejo R, Downey P, Castro R et al (2006) High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 32:713–722
  38. VA/NIH Acute Renal Failure Trial Network (2008) Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 359:7–20
    • View reference on publisher's website
  39. RENAL Replacement Therapy Study Investigators (2009) Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 361:1627–1638
    • View reference on publisher's website
  40. Van Wert R, Friedrich JO, Scales DC et al (2010) High-dose renal replacement therapy for acute kidney injury: systematic review and meta-analysis. Crit Care Med 38:1360–1369
    • View reference on publisher's website
    • View reference on PubMed
  41. Payen D, Mateo J, Cavaillon JM et al (2009) Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 37:803–810
    • View reference on publisher's website
    • View reference on PubMed
  42. Zhou F, Peng Z, Murugan R, Kellum JA (2013) Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med 41:2209–2220
    • View reference on publisher's website
    • View reference on PubMed
  43. Chang T, Tu YK, Lee CT et al (2017) Effects of polymyxin b hemoperfusion on mortality in patients with severe sepsis and septic shock: a systemic review, meta-analysis update, and disease severity subgroup meta-analysis. Crit Care Med 45:e858–e864
    • View reference on publisher's website
    • View reference on PubMed
  44. Nemoto H, Nakamoto H, Okada H et al (2001) Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif 19:361–368
    • View reference on publisher's website
    • View reference on PubMed
  45. Nakamura T, Kawagoe Y, Matsuda T, Koide H (2004) Effect of polymyxin B-immobilized fiber on bone resorption in patients with sepsis. Intensive Care Med 30:1838–1841
  46. Nakamura T, Ushiyama C, Suzuki S et al (2000) Effect of polymyxin B-immobilized fiber hemoperfusion on sepsis-induced rhabdomyolysis with acute renal failure. Nephron 86:210
    • View reference on publisher's website
    • View reference on PubMed
  47. Nakamura T, Ushiyama C, Shoji H, Koide H (2002) Effects of hemoperfusion on serum cardiac troponin T concentrations using polymyxin B-immobilized fibers in septic patients undergoing hemodialysis. ASAIO J 48:41–44
    • View reference on publisher's website
    • View reference on PubMed
  48. Nakamura T, Ushiyama C, Suzuki Y, Shoji H, Shimada N, Koide H (2002) Hemoperfusion with polymyxin B immobilized fibers for urinary albumin excretion in septic patients with trauma. ASAIO J 48:244–248
    • View reference on publisher's website
    • View reference on PubMed
  49. Nakamura T, Ushiyama C, Suzuki Y et al (2003) Hemoperfusion with polymyxin B-immobilized fiber in septic patients with methicillin-resistant Staphylococcus aureus-associated glomerulonephritis. Nephron 94:c33–c39
    • View reference on PubMed
  50. Coudroy R, Payen D, Launey Y, ABDOMIX Group et al (2017) Modulation by polymyxin-B hemoperfusion of inflammatory response related to severe peritonitis. Shock. 47:93–99
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement